AzTrials
AzTrials

AnalgesiaPhase 4NCT06558916

Comparison of the Analgesic Efficacy of Dexketoprofen Trometamol, Meperidine, and Paracetamol in Renal Colic

A Phase 4 study testing Dexketoprofen Trometamol, Meperidine Injectable Solution and Paracetamol in people with Analgesia and Renal Colic, run by Ismail Tekin.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study aimed to compare the effectiveness of intravenous (IV) dexketoprofen trometamol, IV meperidine, and IV paracetamol as analgesics for renal colic in patients at the Emergency Department of Erciyes University Medical School. The double-blind, randomized trial included 90 patients aged 18-65 years. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Analgesia, Renal Colic
What is being tested?
Dexketoprofen Trometamol, Meperidine Injectable Solution and Paracetamol
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
90 participants
Where
No sites listed yet
Study dates
Oct 2015to Dec 2015
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adults aged 18 to 65.
  • Diagnosed with renal colic via anamnesis, physical examination, laboratory, and imaging tests.
  • Provided informed consent to participate in the research.
  • Both genders.

Who cannot join

  • Recent intake of any analgesic medication within six hours prior to arrival.
  • Regular medication schedule.
  • Age under 18 or over 65.
  • Hemodynamically unstable patients.
  • Renal, hepatic, cardiac, or respiratory failure.
  • Allergies to study drugs.
Show all 12Show fewer
  • Pregnant or breastfeeding women.
  • History of renal transplantation.
  • Presence of only one kidney.
  • Serum creatinine levels exceeding 2 mg/dL.
  • History of gastrointestinal bleeding or peptic ulcer.
  • Inability to complete the pain scale due to vision problems.

About this study

Official title: Comparison of the Analgesic Efficacy of Dexketoprofen Trometamol, Meperidine, and Paracetamol in Patients Presenting With Renal Colic

This study aimed to compare the effectiveness of intravenous (IV) dexketoprofen trometamol, IV meperidine, and IV paracetamol as analgesics for renal colic in patients at the Emergency Department of Erciyes University Medical School. The double-blind, randomized trial included 90 patients aged 18-65 years. Patients were divided into three groups of 30, receiving 50 mg IV dexketoprofen trometamol, 50 mg IV meperidine, or 1000 mg IV paracetamol, administered in 250 mL of saline over 15 minutes. Pain intensity was measured at 15, 30, and 60 minutes post-administration using a 100-mm visual analog scale (VAS) and a 4-point verbal rating scale (VRS). Successful treatment was defined as a 50% or greater reduction in VAS score at 30 minutes. Patients with a VAS score of 40 mm or higher at the 30th minute were given fentanyl (1 mcg/kg, intravenously) as a rescue drug.

Read the detailed description

Study design

This clinical trial was conducted at a single center, involving a prospective, randomized, double-blind study. The main objective was to compare the analgesic effectiveness of three different medications-IV dexketoprofen trometamol, IV meperidine, and IV paracetamol in patients who arrived at the emergency department with renal colic.

Selection of participants

Patients who had taken any analgesic medication in the six hours preceding their arrival, those who had a regular medication schedule, individuals under 18 years of age or over 65, hemodynamically unstable patients, patients with renal, hepatic, cardiac, or respiratory failure, those allergic to the drugs used in the study, pregnant or breastfeeding women, those with a history of renal transplantation, patients with only one kidney, individuals with serum creatinine levels exceeding 2 mg/dL, those with a history of gastrointestinal bleeding and peptic ulcer, and patients unable to fill out the pain scale due to vision problems were excluded from the study.

The patients were randomized and numbered using a computer. Ninety eligible patients diagnosed with renal colic and who agreed to participate in the study were included. Thirty patients were assigned to each of the three groups-dexketoprofen trometamol, meperidine and paracetamol.

Interventions

All patients who presented to our emergency department with symptoms and signs indicative of renal colic were interviewed to gather information on their medical history. A detailed physical examination was then performed, and exclusion criteria were assessed. The patients were informed about the study and consent was obtained. Vascular access was established for all patients, and Complete Blood Count (CBC), Blood Urea Nitrogen (BUN) Creatinine, Sodium, Potassium and Aspartate aminotransferase (AST), Alanine transaminase (ALT), and urinalysis tests were requested for diagnosis and differential diagnosis. During the blood draw, the physician who evaluated the patient ordered the analgesic X. Before the evaluation, the patients were informed about the pain scales to be used in the study, namely the visual analog scale (VAS) and verbal rating scale (VRS). The patients then made VAS and VRS markings on the evaluation forms without looking at the previous marking location. Neither the patients nor the physicians knew which study group they were in during the clinical practice phase, as the study was double-blind.

The study drugs were administered to patients suspected of having renal colic in random order: dexketoprofen trometamol IV 50 mg (ampoule containing Dexalgin 50 mg injectable solution), meperidine IV 50 mg (Aldolan 100 mg ampoule) and paracetamol IV 1000 mg (Perfalgan 10 mg/mL infusion solution) was prepared as a 250 mL solution in standard saline, with the same appearance. The nurse who administered the drug was informed about the study, but the nurse who prepared the solution did not know which group the patient was in. The drugs were given as a single dose over 15 minutes.

Direct Urinary System X-ray and Urinary Ultrasound Sonography (USG) were conducted to detect stones and signs of urinary system obstruction in patients with renal colic. In cases where the diagnosis of renal colic was unclear, Computed Tomography was conducted for diagnosis and differential diagnosis. The study included 90 patients of both genders, aged between 18 and 65, who were diagnosed with renal colic after anamnesis, physical examination, laboratory and imaging tests, and who gave their consent to participate in the research. Statistical analyses were then performed.

If any unexpected effect was observed in the patients during the study period, the patient did not accept the treatment or wanted to leave the study; such patients were excluded from the study in the preparation phase. Fortunately, no such situation was encountered during the follow-ups.

Methods of measurements

The time at which treatment began was recorded as 0th minutes and pain levels were measured using the VAS scale, which ranges from "0 mm (no pain)" to "100 mm (unbearable pain)". The pain levels were measured before treatment and at the 15th, 30th and 60th minutes after the treatment. Pain severity was evaluated using VRS and classified as "none"-"mild"-"moderate"-"severe".

A treatment was considered successful if there was a 50% or greater reduction in the VAS score at the 30th minute [8]. If a patient's VAS score was ≥40 mm at the 30th minute, they were given 1 mcg/kg of Fentanyl IV as a rescue medication. All patients were monitored for at least 60 minutes, and any side effects and vital signs were recorded during this period.

Data analysis

Statistical analysis conducted in this study involved the use of various methods such as t-test independent samples, one-way variance analysis, and variance analysis in repeated measurements. The categorical variables were analyzed using the chi-square test. The numerical variables were expressed as arithmetic mean standard deviation (mean ± SD). Any p-value less than 0.05 was considered statistically significant. The statistical analysis was performed using version 22 of the "SPSS for Windows" package program (IBM, Armonk, NY, United States).

Being tested
Dexketoprofen Trometamol, Meperidine Injectable Solution, Paracetamol, Fentanyl
Keywords
Analgesic efficacy, Dexketoprofen trometamol, Emergency department, Meperidine, Paracetamol, Renal colic
Medical subject headings
Agnosia, Renal Colic, Emergencies

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Dexketoprofen TrometamolDrug

    Also called Arveles, Dexalgin

  • Meperidine Injectable SolutionDrug

    Also called Pethidine, Aldolan

  • ParacetamolDrug

    Also called Acetaminophen, Parol

  • FentanylDrug

    Also called Sublimaze

    Patients with a VAS score of 40 mm or higher at the 30th minute were given fentanyl (1 mcg/kg, intravenously) as a rescue drug.

Study groups in NCT06558916
Study groupRoleWhat they receive
Dexketoprofen trometamolExperimentalThe study drugs were administered to patients suspected of having renal colic in random order: dexketoprofen trometamol IV 50 mg (ampoule containing Dexalgin 50 mg injectable solution) was prepared as a 250 mL solution in standard saline, with the same appearance. The drugs were given as a single dose over 15 minutes.
Receives: Drug: Dexketoprofen Trometamol; Drug: Fentanyl
MeperidineExperimentalThe study drugs were administered to patients suspected of having renal colic in random order: meperidine IV 50 mg (Aldolan 100 mg ampoule) was prepared as a 250 mL solution in standard saline, with the same appearance. The drugs were given as a single dose over 15 minutes.
Receives: Drug: Meperidine Injectable Solution; Drug: Fentanyl
ParacetamolExperimentalThe study drugs were administered to patients suspected of having renal colic in random order: paracetamol IV 1000 mg (Perfalgan 10 mg/mL infusion solution) was prepared as a 250 mL solution in standard saline, with the same appearance.The drugs were given as a single dose over 15 minutes.
Receives: Drug: Paracetamol; Drug: Fentanyl

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. VAS score change at the 30th minute

    The time at which treatment began was recorded as 0th minutes and pain levels were measured using the VAS scale, which ranges from "0 mm (no pain)" to "100 mm (unbearable pain)". The pain levels were measured before treatment and at the 15th, 30th and 60th minutes after the treatment. Pain severity was evaluated using VRS and classified as "none"-"mild"-"moderate"-"severe".

    A treatment was considered successful if there was a 50% or greater reduction in the VAS score at the 30th minute.

    Measured: 0th minute and 30th minute

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Aug 2024
  2. Study startOct 2015
  3. Primary completionDec 2015
  4. Study completionDec 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
The patients were randomized and numbered using a computer. Ninety eligible patients diagnosed with renal colic and who agreed to participate in the study were included. Thirty patients were assigned to each of the three groups-dexketoprofen trometamol, meperidine and paracetamol.The study drugs were administered to patients suspected of having renal colic in random order: dexketoprofen trometamol IV 50 mg (ampoule containing Dexalgin 50 mg injectable solution), meperidine IV 50 mg (Aldolan 100 mg ampoule) and paracetamol IV 1000 mg (Perfalgan 10 mg/mL infusion solution) was prepared as a 250 mL solution in standard saline, with the same appearance. The drugs were given as a single dose over 15 minutes.
Masking
Double blind
Who is masked
Participant, Care provider
Enrolment
90 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06558916
Sponsor's protocol ID
ErciyesUniversity-IT01
Status last verified
Aug 2024
First submitted
14 Aug 2024
Last updated
19 Aug 2024
Results posted
No
FDA-regulated drug
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Dexketoprofen Trometamol, Meperidine Injectable Solution and Paracetamol in people with Analgesia and Renal Colic, run by Ismail Tekin.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 19 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

VAS score change at the 30th minute (time frame: 0th minute and 30th minute). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Aug 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in